Literature DB >> 28179429

SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins.

Chetan Sood1, Mariana Marin1, Ajit Chande2, Massimo Pizzato2, Gregory B Melikyan3.   

Abstract

The host proteins, SERINC3 and SERINC5, have been recently shown to incorporate into HIV-1 particles and compromise their ability to fuse with target cells, an effect that is antagonized by the viral Nef protein. Envelope (Env) glycoproteins from different HIV-1 isolates exhibit a broad range of sensitivity to SERINC-mediated restriction, and the mechanism by which SERINCs interfere with HIV-1 fusion remains unclear. Here, we show that incorporation of SERINC5 into virions in the absence of Nef inhibits the formation of small fusion pores between viruses and cells. Strikingly, we found that SERINC5 promotes spontaneous functional inactivation of sensitive but not resistant Env glycoproteins. Although SERINC5-Env interaction was not detected by co-immunoprecipitation, incorporation of this protein enhanced the exposure of the conserved gp41 domains and sensitized the virus to neutralizing antibodies and gp41-derived inhibitory peptides. These results imply that SERINC5 restricts HIV-1 fusion at a step prior to small pore formation by selectively inactivating sensitive Env glycoproteins, likely through altering their conformation. The increased HIV-1 sensitivity to anti-gp41 antibodies and peptides suggests that SER5 also delays refolding of the remaining fusion-competent Env trimers.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Env inactivation; HIV neutralization; conformational changes; fluorescence; hemifusion; host defense; membrane fusion; membrane-proximal extracellular domain; peptides; virus entry

Mesh:

Substances:

Year:  2017        PMID: 28179429      PMCID: PMC5392591          DOI: 10.1074/jbc.M117.777714

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

1.  Distinct requirements for HIV-cell fusion and HIV-mediated cell-cell fusion.

Authors:  Naoyuki Kondo; Mariana Marin; Jeong Hwa Kim; Tanay M Desai; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2015-01-14       Impact factor: 5.157

2.  Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.

Authors:  Elena Gustchina; John M Louis; Carole A Bewley; G Marius Clore
Journal:  J Mol Biol       Date:  2006-09-12       Impact factor: 5.469

3.  HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion.

Authors:  Marielle Cavrois; Jason Neidleman; Wes Yonemoto; David Fenard; Warner C Greene
Journal:  Virology       Date:  2004-10-10       Impact factor: 3.616

4.  Simplified equation to extract diffusion coefficients from confocal FRAP data.

Authors:  Minchul Kang; Charles A Day; Anne K Kenworthy; Emmanuele DiBenedetto
Journal:  Traffic       Date:  2012-10-10       Impact factor: 6.215

5.  Fusion from without directed by human immunodeficiency virus particles.

Authors:  F Clavel; P Charneau
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

6.  HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes.

Authors:  Kosuke Miyauchi; Yuri Kim; Olga Latinovic; Vladimir Morozov; Gregory B Melikyan
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

7.  Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion.

Authors:  G B Melikyan; R M Markosyan; H Hemmati; M K Delmedico; D M Lambert; F S Cohen
Journal:  J Cell Biol       Date:  2000-10-16       Impact factor: 10.539

8.  Visualization of Content Release from Cell Surface-Attached Single HIV-1 Particles Carrying an Extra-Viral Fluorescent pH-Sensor.

Authors:  Chetan Sood; Mariana Marin; Caleb S Mason; Gregory B Melikyan
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

9.  Functional Interplay Between Murine Leukemia Virus Glycogag, Serinc5, and Surface Glycoprotein Governs Virus Entry, with Opposite Effects on Gammaretroviral and Ebolavirus Glycoproteins.

Authors:  Yadvinder S Ahi; Shu Zhang; Yashna Thappeta; Audrey Denman; Amin Feizpour; Suryaram Gummuluru; Bjoern Reinhard; Delphine Muriaux; Matthew J Fivash; Alan Rein
Journal:  mBio       Date:  2016-11-22       Impact factor: 7.867

10.  Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum.

Authors:  Lusine Demirkhanyan; Mariana Marin; Wuyuan Lu; Gregory B Melikyan
Journal:  PLoS Pathog       Date:  2013-06-13       Impact factor: 6.823

View more
  63 in total

1.  CD4 Expression and Env Conformation Are Critical for HIV-1 Restriction by SERINC5.

Authors:  Xihe Zhang; Jing Shi; Xusheng Qiu; Qingqing Chai; Dylan A Frabutt; Richard C Schwartz; Yong-Hui Zheng
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

Review 2.  Exposing HIV's weaknesses.

Authors:  Philip R Tedbury; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2017-04-07       Impact factor: 5.157

3.  Differential Pressures of SERINC5 and IFITM3 on HIV-1 Envelope Glycoprotein over the Course of HIV-1 Infection.

Authors:  Saina Beitari; Qinghua Pan; Andrés Finzi; Chen Liang
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

4.  CD4-Dependent Modulation of HIV-1 Entry by LY6E.

Authors:  Jingyou Yu; Chen Liang; Shan-Lu Liu
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

5.  HIV fusion: Catch me if you can.

Authors:  Solène Denolly; François-Loïc Cosset
Journal:  J Biol Chem       Date:  2020-11-06       Impact factor: 5.157

Review 6.  Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes.

Authors:  Ryan P Staudt; John J Alvarado; Lori A Emert-Sedlak; Haibin Shi; Sherry T Shu; Thomas E Wales; John R Engen; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2020-08-29       Impact factor: 5.157

7.  Nef homodimers down-regulate SERINC5 by AP-2-mediated endocytosis to promote HIV-1 infectivity.

Authors:  Ryan P Staudt; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2020-09-01       Impact factor: 5.157

8.  SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.

Authors:  Austin Featherstone; Christopher Aiken
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

9.  Full-Length Glycosylated Gag of Murine Leukemia Virus Can Associate with the Viral Envelope as a Type I Integral Membrane Protein.

Authors:  Tyler Milston Renner; Kasandra Bélanger; Cindy Lam; María Carla Rosales Gerpe; Joanne Eileen McBane; Marc-André Langlois
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

10.  Murine Leukemia Virus Glycosylated Gag Reduces Murine SERINC5 Protein Expression at Steady-State Levels via the Endosome/Lysosome Pathway to Counteract SERINC5 Antiretroviral Activity.

Authors:  Sunan Li; Iqbal Ahmad; Jing Shi; Bin Wang; Changqing Yu; Lixin Zhang; Yong-Hui Zheng
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.